Rewiring T Cell Metabolism to Enhance CAR T Cell Function in Solid Tumor Microenvironments

Area of Science:

• Immunology
• Oncology
• Metabolic Engineering

Background:

• Chimeric antigen receptor (CAR) T cells show success in blood cancers but fail in solid tumors.
• The tumor microenvironment (TME) is hostile, with low oxygen, nutrients, and toxic metabolites.
• The TME suppresses immune cell activity, limiting CAR T cell efficacy.

Purpose of the Study:

• To review strategies for metabolic reprogramming of CAR T cells.
• To overcome TME-induced suppression and enhance CAR T cell performance in solid tumors.

Main Methods:

• Evaluation of preclinical and translational studies.
• Focus on engineering CAR T cells for TME resistance.
• Investigated strategies include hypoxia resistance, nutrient utilization, and metabolite counteraction.

Main Results:

• Engineered CAR T cells resist hypoxia and high lactate.
• Enhanced nutrient uptake via transporter overexpression.
• Inhibition of adenosine-driven pathways improves CAR T cell persistence, memory, and function.

Conclusions:

• Metabolic reprogramming is crucial for CAR T cell therapy in solid tumors.
• Integration with conventional CAR design unlocks therapeutic potential.
• Innovation in metabolic engineering is key for clinical translation.